Simrat Randhawa - 12 Mar 2026 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
EVP, Head of R&D
Signature
/s/ Adam Veness, as attorney-in-fact for Simrat Randhawa
Issuer symbol
DNTH
Transactions as of
12 Mar 2026
Net transactions value
-$2,756,468
Form type
4
Filing time
13 Mar 2026, 20:30:03 UTC
Previous filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Randhawa Simrat EVP, Head of R&D C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK /s/ Adam Veness, as attorney-in-fact for Simrat Randhawa 13 Mar 2026 0001992260

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNTH Common Stock Options Exercise +7,998 $8.44* 7,998 12 Mar 2026 Direct F1
transaction DNTH Common Stock Options Exercise +5,000 +63% $17.88* 12,998 12 Mar 2026 Direct F1
transaction DNTH Common Stock Options Exercise +8,332 +64% $21.77* 21,330 12 Mar 2026 Direct F1
transaction DNTH Common Stock Options Exercise +12,500 +59% $22.07* 33,830 12 Mar 2026 Direct F1
transaction DNTH Common Stock Sale $2,756,468 -33,830 -100% $81.48 0 12 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Options Exercise -7,998 -67% $0.000000* 3,998 12 Mar 2026 Common Stock 7,998 $8.44 Direct F1, F2
transaction DNTH Stock Option (Right to Buy) Options Exercise -5,000 -6.6% $0.000000* 71,184 12 Mar 2026 Common Stock 5,000 $17.88 Direct F1, F3
transaction DNTH Stock Option (Right to Buy) Options Exercise -8,332 -13% $0.000000* 54,174 12 Mar 2026 Common Stock 8,332 $21.77 Direct F1, F4
transaction DNTH Stock Option (Right to Buy) Options Exercise -12,500 -11% $0.000000* 106,250 12 Mar 2026 Common Stock 12,500 $22.07 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
F2 The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3 The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F4 The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F5 The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.